CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Sign Up to like & getrecommendations! Published in 2017 at "Human gene therapy"
DOI: 10.1089/hum.2017.126
Abstract: The treatment of leukemia/lymphoma by chimeric antigen receptor (CAR) redirected T cells with specificity for CD19 induced complete remissions in the majority of patients, with a realistic hope for cure. However, recent follow-up data revealed… read more here.
Keywords: bispecific car; cd19; cd20 cd19; car cells ... See more keywords
A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210226
Abstract: Background: Despite the promising outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating relapsed or refractory multiple myeloma (RRMM), addressing extramedullary disease (EMD) in this context remains a therapeutic challenge. This study aimed to… read more here.
Keywords: disease; anti bcma; gprc5d bispecific; bispecific car ... See more keywords